IRLAB Q1: Multiple potential roads ahead - Redeye

Redeye provides a research update following IRLAB's Q1 report. Following the ambiguous results from the Pirepemat phase IIb study, we believe that the company's direction and prioritization regarding business development and clinical activity ahead will be crucial.

Länk till analysen i sin helhet: https://www.redeye.se/research/1099954/irlab-q1-multiple-potential-roads-ahead?utm_source=finwire&utm_medium=RSS